Cargando…

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes

(1) Background: Hormone receptor positive breast cancer is a subtype of breast cancer with relatively good prognosis, but luminal B (HER–2 negative) breast cancer has a higher risk of recurrence and metastasis. Patients with endocrine therapy resistance and chemotherapy insensitivity have poor progn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fan, Li, Jiayi, Zhang, Hong, Zhang, Shuang, Ye, Jingming, Cheng, Yuanjia, Liu, Qian, Xin, Ling, Xiang, Hongyu, Liu, Yinhua, Duan, Xuening, Xu, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785183/ https://www.ncbi.nlm.nih.gov/pubmed/36556209 http://dx.doi.org/10.3390/jpm12121988

Ejemplares similares

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
por: Li, Jiayi, et al.
Publicado: (2022)

A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer
por: Ye, Jingming, et al.
Publicado: (2017)

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
por: Xu, Ling, et al.
Publicado: (2017)

Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)
por: Cheng, Yuanjia, et al.
Publicado: (2022)

Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing
por: Xiang, Hongyu, et al.
Publicado: (2020)

Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)
por: Xin, Ling, et al.
Publicado: (2022)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021)

Comparison of adverse effects of anti-tumor therapy for breast cancer shortly after COVID-19 diagnosis vs. the control period
por: Ding, Mao, et al.
Publicado: (2023)

Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient
por: Zhang, Zhuo, et al.
Publicado: (2021)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

A Clinical–Radiomics Model for Predicting Axillary Pathologic Complete Response in Breast Cancer With Axillary Lymph Node Metastases
por: Gan, Liangyu, et al.
Publicado: (2021)

Histo- and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading
por: Zhang, Shuang, et al.
Publicado: (2020)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
por: Khadela, Avinash, et al.
Publicado: (2022)

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
por: Yang, Zheng‐Jun, et al.
Publicado: (2022)

Validation of CPS+EG, Neo‐Bioscore, and modified Neo‐Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China
por: Xu, Ling, et al.
Publicado: (2018)

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
por: Utsumi, Toshiaki, et al.
Publicado: (2021)

High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer: pCDK2 in luminal androgen receptor TNBC
por: Jin, Zining, et al.
Publicado: (2022)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer
por: Ushimado, Kaori, et al.
Publicado: (2019)

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy
por: Li, Peng, et al.
Publicado: (2022)

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
por: Alvarez-Lopez, I., et al.
Publicado: (2020)

A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
por: Yang, Xue, et al.
Publicado: (2023)

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer
por: Park, Chansub, et al.
Publicado: (2016)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER
por: Rajc, Jasmina, et al.
Publicado: (2018)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
por: Zong, Yu, et al.
Publicado: (2014)

The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis
por: Zhang, Chi, et al.
Publicado: (2019)

BI-RADS 3–5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype
por: Cen, DongZhi, et al.
Publicado: (2017)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Expression of Autophagy-Related Proteins According to Androgen Receptor and HER-2 Status in Estrogen Receptor-Negative Breast Cancer
por: Kim, Ji-Ye, et al.
Publicado: (2014)

Androgen Inhibits Abdominal Fat Accumulation and Negatively Regulates the PCK1 Gene in Male Chickens
por: Duan, Jinlin, et al.
Publicado: (2013)

A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8(th) Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer
por: Xu, Ling, et al.
Publicado: (2017)

Luminal B breast tumors are not HER2 positive – authors' response
por: Tamimi, Rulla M, et al.
Publicado: (2008)

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study
por: Eom, Yong Hwa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g4nji507929hjla7bsfs1jng87